Overview of inhibitors
1University of Lund, Malmö, Sweden. Jan.astermark@med.lu.se
Seminars in Hematology
|May 13, 2006
Summary
Inhibitor antibodies in hemophilia patients reduce treatment effectiveness. Further research into genetics, environment, and the immune system is crucial for developing new therapies.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- Inhibitory antibodies in hemophilia patients complicate treatment with factor concentrates.
- Factors influencing inhibitor development include genetics, factor concentrate type, and environmental influences.
- Genetic predisposition and immune system response are implicated in inhibitor formation.
Purpose of the Study:
- To summarize the factors influencing inhibitor development in hemophilia.
- To highlight the need for further research into genetic and immunological markers.
- To underscore the challenge of developing novel therapies for inhibitor management.
Main Methods:
- Literature review and synthesis of existing research on hemophilia inhibitors.
- Analysis of epidemiological data suggesting genetic and environmental influences.
- Discussion of the immunological basis of inhibitor antibody development.
Main Results:
- Genetic factors, such as familial incidence and ethnic variations, suggest a predisposition to inhibitor development.
- Environmental factors and the type of factor concentrate may influence inhibitor incidence.
- Immunological challenges in patients indicate a role for the immune response system.
Conclusions:
- Developing effective therapies for hemophilia inhibitors requires a comprehensive understanding of genetic, environmental, and immunological factors.
- Identification of specific genetic markers is needed to predict inhibitor risk.
- Further investigation into the immune response is essential for advancing treatment strategies.
Related Concept Videos
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
00:46Feedback Inhibition
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...